Comparative Pharmacology
Head-to-head clinical analysis: EFAVIRENZ EMTRICITABINE TENOFOVIR DISOPROXIL FUMARATE versus EMTRICITABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFAVIRENZ EMTRICITABINE TENOFOVIR DISOPROXIL FUMARATE versus EMTRICITABINE.
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE vs EMTRICITABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds reversibly to HIV-1 reverse transcriptase, causing a conformational change and inhibiting RNA-dependent and DNA-dependent DNA polymerase activity. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that, after intracellular phosphorylation, competes with deoxycytidine 5'-triphosphate and incorporates into viral DNA, causing chain termination. Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate that, after hydrolysis and phosphorylation, inhibits HIV-1 reverse transcriptase and hepatitis B virus DNA polymerase by competing with deoxyadenosine 5'-triphosphate and causing DNA chain termination.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
One tablet (efavirenz 600 mg / emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg) orally once daily on an empty stomach, preferably at bedtime.
200 mg orally once daily, typically in combination with other antiretroviral agents.
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
None Documented
Efavirenz: 40-55 hours (single dose), 52-76 hours (steady state). Emtricitabine: 10 hours (healthy), extended to >20 hours in renal impairment. Tenofovir: 17 hours (healthy), prolonged in renal impairment (up to 7 days with CrCl <30 mL/min).
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Efavirenz: ~14-34% excreted in urine (primarily as metabolites) and ~16-61% in feces. Emtricitabine: ~86% excreted unchanged in urine and ~14% as metabolites. Tenofovir disoproxil fumarate: ~70-80% excreted unchanged in urine via glomerular filtration and active tubular secretion.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Category A/B
Category C
NRTI
Antiretroviral, NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."